Background Background Epidemiological and
Epidemiological and clinical studies suggest that increased clinical studies suggestthat increased intake of eicosapentaenoic acid (EPA) intake of eicosapentaenoic acid (EPA) alleviates unipolar depression. alleviates unipolar depression.
Aims Aims To examine the efficacy of EPA in
To examine the efficacy of EPA in treating depression in bipolar disorder. treating depression in bipolar disorder.
Method Method In a12-week, double-blind
In a12-week, double-blind study individuals with bipolar depression study individuals with bipolar depression were randomly assigned to adjunctive were randomly assigned to adjunctive treatment with placebo ( treatment with placebo (n n¼26) or with 26) or with 1g/day ( 1g/day (n n¼24) or 2 g/day ( 24) or 2 g/day (n n¼25) of ethyl-25) of ethyl-EPA. Primary efficacy was assessed by the EPA. Primary efficacy was assessed by the Hamilton Rating Scale for Depression Hamilton Rating Scale for Depression (HRSD), with changes in theYoung Mania (HRSD), with changes in theYoung Mania Rating Scale and Clinical Global Rating Scale and Clinical Global Impression Scale (CGI) as secondary Impression Scale (CGI) as secondary outcome measures. outcome measures.
Results

Results There was no apparent benefit
There was no apparent benefit of 2 g over1g ethyl-EPA daily. Significant of 2 g over1g ethyl-EPA daily. Significant improvement was noted with ethyl-EPA improvement was noted with ethyl-EPA treatment compared with placebo in the treatment compared with placebo in the HRSD ( HRSD (P P¼0.04) and the CGI ( 0.04) and the CGI (P P¼0.004) 0.004) scores.Both doses were well tolerated. scores.Both doses were well tolerated.
Conclusions Conclusions Adjunctive ethyl-EPA is
Adjunctive ethyl-EPA is an effective and well-tolerated an effective and well-tolerated intervention in bipolar depression. intervention in bipolar depression.
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In spite of the often dramatic nature of In spite of the often dramatic nature of mania, the depressive phases of bipolar dismania, the depressive phases of bipolar disorder can contribute most to poor outcome order can contribute most to poor outcome (MacQueen (MacQueen et al et al, 2001) . Treatment is both , 2001). Treatment is both understudied and clinically complicated understudied and clinically complicated . Interest . Interest has grown in the potential role of omegahas grown in the potential role of omega-3 fatty acids such as eicosapentaenoic acid 3 fatty acids such as eicosapentaenoic acid (EPA), which are found in certain plants (EPA), which are found in certain plants and marine animals such as 'oily' fish. A and marine animals such as 'oily' fish. A possible role in the treatment of bipolar possible role in the treatment of bipolar depression is suggested by studies of fish depression is suggested by studies of fish consumption (Hibbeln, 1998; Noaghiul & consumption (Hibbeln, 1998; Noaghiul & Hibbeln, 2003) , blood fatty acid biochemisHibbeln, 2003), blood fatty acid biochemistry (Adams try (Adams et al et al, 1996) and clinical trials , 1996) and clinical trials (Horrobin & Peet, 2001; Nemets (Horrobin & Peet, 2001; Nemets et al et al, , 2002; Puri 2002; Puri et al et al, 2002) . There is some , 2002). There is some evidence that they might prolong interevidence that they might prolong interepisode remission in people with bipolar episode remission in people with bipolar disorder (Stoll disorder (Stoll et al et al, 1999) . Our aim there-, 1999). Our aim therefore was to examine the efficacy and tolerfore was to examine the efficacy and tolerability of ethyl-EPA as an adjunctive ability of ethyl-EPA as an adjunctive treatment for bipolar depression. treatment for bipolar depression.
METHOD METHOD
Study design Study design
The study was a single-centre, 12-week, The study was a single-centre, 12-week, double-blind randomised comparison of double-blind randomised comparison of ethyl-EPA at 1 g or 2 g/day ethyl-EPA at 1 g or 2 g/day v.
v. placebo placebo (par (paraffin oil) as adjunctive treatment in affin oil) as adjunctive treatment in outout-patients with bipolar depression. The patients with bipolar depression. The decision to examine the efficacy of two decision to examine the efficacy of two doses of ethyl-EPA was based on previous doses of ethyl-EPA was based on previous studies that had found 2 g/day of ethylstudies that had found 2 g/day of ethyl-EPA to be the optimal dose for EPA to be the optimal dose for schizophrenia (Peet schizophrenia (Peet et al et al, 2002) and 1 g/ , 2002) and 1 g/ day for unipolar depression (Horrobin & day for unipolar depression (Horrobin & Peet, 2001) . Peet, 2001) .
Because of lack of data on the efficacy Because of lack of data on the efficacy of ethyl-EPA in bipolar depression at the of ethyl-EPA in bipolar depression at the time of initiation of the study, formal samtime of initiation of the study, formal sample size calculations were not possible. This ple size calculations were not possible. This study was therefore not powered to detect study was therefore not powered to detect changes between the three treatment groups changes between the three treatment groups but to allow preliminary data to be colbut to allow preliminary data to be collected regarding treatment effect size (if lected regarding treatment effect size (if any) for planning future studies. The study any) for planning future studies. The study was conducted at the Institute of was conducted at the Institute of Psychiatry, London, according to the prinPsychiatry, London, according to the principles of the Declaration of Helsinki and ciples of the Declaration of Helsinki and was approved by the local ethics commitwas approved by the local ethics committee. Participants were recruited following tee. Participants were recruited following referral from their treating physicians or referral from their treating physicians or through advertisements in patient groups' through advertisements in patient groups' newsletters. After a complete description newsletters. After a complete description of the study, written informed consent of the study, written informed consent was obtained from all participants and was obtained from all participants and signed agreement was obtained from their signed agreement was obtained from their treating physicians. treating physicians.
Participants were then screened to conParticipants were then screened to confirm their eligibility. Eligible participants firm their eligibility. Eligible participants were males or females between the ages were males or females between the ages 18 and 70 years who met criteria for 18 and 70 years who met criteria for bipolar disorder I or II as set out in the bipolar disorder I or II as set out in the DSM-IV (American Psychiatric Associa-DSM-IV (American Psychiatric Association, 1994) and as determined by personal tion, 1994) and as determined by personal interview using the research version of the interview using the research version of the Structured Clinical Interview for DSM-IV Structured Clinical Interview for DSM-IV (First (First et al et al, 1994) . , 1994) . Participants were also required to score Participants were also required to score at least 10 on the 17-item Hamilton Rating at least 10 on the 17-item Hamilton Rating Scale for Depression (HRSD-17 Hamilton, Scale for Depression (HRSD-17 Hamilton, 1960) . Individuals were not included if: 1960). Individuals were not included if: there was evidence of alcohol or illicit subthere was evidence of alcohol or illicit substance dependence, as defined by DSM-IV stance dependence, as defined by DSM-IV criteria, over the preceding 6 months; the criteria, over the preceding 6 months; the severity of their bipolar disorder was such severity of their bipolar disorder was such that participation in a clinical trial was that participation in a clinical trial was not appropriate because of risk of imminent not appropriate because of risk of imminent suicide or admission to hospital; there was suicide or admission to hospital; there was a history of poor adherence to treatment a history of poor adherence to treatment and poor attendance at appointments; there and poor attendance at appointments; there was a concurrent medical condition or was a concurrent medical condition or medication that could have accounted for medication that could have accounted for the depressive episode; they had clinically the depressive episode; they had clinically significant abnormalities on routine biosignificant abnormalities on routine biochemistry and haematology tests; they chemistry and haematology tests; they were on anticoagulants; they had known were on anticoagulants; they had known allergies to the ingredients of the study allergies to the ingredients of the study medication; they had taken fatty acid supmedication; they had taken fatty acid supplements or had been exposed to study plements or had been exposed to study medication in the preceding 12 weeks; or, medication in the preceding 12 weeks; or, in the case of women, they were pregnant in the case of women, they were pregnant or lactating, or of child-bearing potential or lactating, or of child-bearing potential and not taking adequate contraceptive and not taking adequate contraceptive precautions. precautions.
Eligible participants underwent a baseEligible participants underwent a baseline assessment using the HRSD, the Young line assessment using the HRSD, the Young Mania Rating Scale (YMRS; Young Mania Rating Scale (YMRS; Young et al et al, , 1978) and the Clinical Global Impression 1978) and the Clinical Global Impression Scale (CGI; Guy, 2000). Information about Scale (CGI; Guy, 2000) . Information about their concomitant medication was also retheir concomitant medication was also recorded corded at baseline. There were no restricat baseline. There were no restrictions to the type and dose of psychotropic tions to the type and dose of psychotropic medication that they were receiving upon medication that they were receiving upon study entry. Participants were randomised study entry. Participants were randomised only if existing psychotropic medication only if existing psychotropic medication had remained unchanged (i.e. the same type had remained unchanged (i.e. the same type and dose) for 8 weeks prior to baseline and dose) for 8 weeks prior to baseline assessment. If they were medication free, assessment. If they were medication free, then this also had to have been the case then this also had to have been the case for the preceding 8 weeks. for the preceding 8 weeks.
Following baseline assessment, individFollowing baseline assessment, individuals were randomly assigned to one of the uals were randomly assigned to one of the three treatment arms on a 1:1:1 basis using three treatment arms on a 1:1:1 basis using block-balanced randomisation codes (five block-balanced randomisation codes (five patients per block). The randomisation patients per block). The randomisation codes were unmasked after the last patient codes were unmasked after the last patient had completed the last visit. Randomisation had completed the last visit. Randomisation was implemented by giving participants was implemented by giving participants numbered containers containing soft gelanumbered containers containing soft gelatin capsules. Each person was given three tin capsules. Each person was given three containers, one for each month of the containers, one for each month of the study, and was asked to return them at study, and was asked to return them at the appropriate assessments for a capsule the appropriate assessments for a capsule count to assess adherence. All participants count to assess adherence. All participants were prescribed four identical-looking capwere prescribed four identical-looking capsules daily, taken in two divided doses sules daily, taken in two divided doses with food. Each capsule contained either with food. Each capsule contained either 500 mg ethyl-EPA (purity 500 mg ethyl-EPA (purity 4 495%; supplied 95%; supplied as LAX-101) or 500 mg liquid paraffin. as LAX-101) or 500 mg liquid paraffin. Liquid paraffin is an inert compound comLiquid paraffin is an inert compound commonly used as a lubricant laxative. Its monly used as a lubricant laxative. Its usual laxative dose ranges between 15 and usual laxative dose ranges between 15 and 30 g/day. At the doses used in this study 30 g/day. At the doses used in this study (1-2 g/day) it would not be expected to (1-2 g/day) it would not be expected to have any laxative effect other than that of have any laxative effect other than that of the same dose of any food oil. the same dose of any food oil.
Further assessments were conducted at Further assessments were conducted at weeks 4 and 12 using the same rating scales weeks 4 and 12 using the same rating scales as at the baseline visit; changes in concomias at the baseline visit; changes in concomitant medication, adherence to study tant medication, adherence to study medication and adverse events were also medication and adverse events were also recorded. Treating clinicians were allowed recorded. Treating clinicians were allowed to change participants' medication only if to change participants' medication only if there was significant deterioration in their there was significant deterioration in their mental state or emergent side-effects. mental state or emergent side-effects.
Outcome measures Outcome measures
The primary outcome measure was change The primary outcome measure was change in the HRSD score from baseline to the in the HRSD score from baseline to the 12-week end-point. Secondary outcome 12-week end-point. Secondary outcome measures were changes from baseline to measures were changes from baseline to end-point in the YMRS and CGI scores. end-point in the YMRS and CGI scores. The percentage of participants requiring The percentage of participants requiring adjustment of their medication and the time adjustment of their medication and the time to change of medication was also a secondto change of medication was also a secondary outcome measure. Adverse events were ary outcome measure. Adverse events were also recorded and evaluated in terms of also recorded and evaluated in terms of their onset, intensity and outcome. In order their onset, intensity and outcome. In order to assess whether any treatment effects to assess whether any treatment effects could be attributed to participants guessing could be attributed to participants guessing their treatment allocation, they were asked their treatment allocation, they were asked to state whether they thought they had reto state whether they thought they had received active treatment or not and to justify ceived active treatment or not and to justify their choice. Adherence to study medication their choice. Adherence to study medication was monitored by pill-counting. was monitored by pill-counting.
Statistical analysis Statistical analysis
Pearson's Pearson's w w 2 2 , two-tailed Student's , two-tailed Student's t t-tests -tests and one-way analysis of variance were used and one-way analysis of variance were used to compare the distribution of categorical to compare the distribution of categorical data and continuous data respectively data and continuous data respectively between the groups. To compare the clinibetween the groups. To compare the clinical outcomes of the ethyl-EPA and placebo cal outcomes of the ethyl-EPA and placebo groups we used linear regression analysis groups we used linear regression analysis on an intent-to-treat basis. With the regreson an intent-to-treat basis. With the regression models we were able to control for sion models we were able to control for baseline scores in a similar way to using baseline scores in a similar way to using analysis of variance but with the added analysis of variance but with the added benefit of being able to use bootstrapping benefit of being able to use bootstrapping techniques to generate robust confidence techniques to generate robust confidence intervals in the presence of data that intervals in the presence of data that followed a non-normal distribution. Bootfollowed a non-normal distribution. Bootstrapping involves resampling from the strapping involves resampling from the original data a sufficient number of times original data a sufficient number of times (5000 in this study) in order to approxi-(5000 in this study) in order to approximate the population from which the sample mate the population from which the sample is drawn; this does not involve prior is drawn; this does not involve prior assumptions as to the form of this disassumptions as to the form of this distribution. In the results that follow the tribution. In the results that follow the mean difference and standard errors (s.e.) mean difference and standard errors (s.e.) are reported along with the bootstrapped are reported along with the bootstrapped 95% confidence intervals of the difference. 95% confidence intervals of the difference. The Cohen's The Cohen's d d effect sizes were also effect sizes were also calculated to determine the magnitude of calculated to determine the magnitude of the differences between the treatment and the differences between the treatment and placebo groups in depression and mania placebo groups in depression and mania ratings . ratings .
The study was funded by Laxdale Ltd, The study was funded by Laxdale Ltd, who collaborated with the authors on study who collaborated with the authors on study design but were not involved in data collecdesign but were not involved in data collection, analysis or interpretation, writing the tion, analysis or interpretation, writing the report or in the decision to submit for pubreport or in the decision to submit for publication. Study materials were packaged lication. Study materials were packaged and masked by the Clinical Trial Supplies and masked by the Clinical Trial Supplies Company and adverse events were moniCompany and adverse events were monitored by Clintrials Research Ltd; neither tored by Clintrials Research Ltd; neither was involved in any other aspect of the was involved in any other aspect of the study. study.
RESULTS RESULTS
A total of 93 people were screened for elig-A total of 93 people were screened for eligibility. The flow of potential participants is ibility. The flow of potential participants is shown in Fig. 1 . Of these, 18 were ineligishown in Fig. 1 . Of these, 18 were ineligible because of an incorrect diagnosis ble because of an incorrect diagnosis ( (n n¼3), an HRSD score below 10 ( 3), an HRSD score below 10 (n n¼4), 4), concurrent substance misuse ( concurrent substance misuse (n n¼1), medi-1), medical conditions ( cal conditions (n n¼2), frequent medication 2), frequent medication changes ( changes (n n¼5) and withdrawal of consent 5) and withdrawal of consent prior to randomisation ( prior to randomisation (n n¼3). The remain-3 Table 2 summarises participants' medication at study marises participants' medication at study entry. entry.
In total, nine individuals stopped taking In total, nine individuals stopped taking the study medication, six from the placebo the study medication, six from the placebo group and three of those randomised to group and three of those randomised to receive 2 g/day ethyl-EPA. For all but two receive 2 g/day ethyl-EPA. For all but two of these lack of efficacy was the reason of these lack of efficacy was the reason for discontinuing study medication. Of the for discontinuing study medication. Of the other two, one misunderstood the study other two, one misunderstood the study protocol and stopped study medication protocol and stopped study medication when their concomitant medication was when their concomitant medication was changed and the other did not like the apchanged and the other did not like the appearance of the study medication. Howpearance of the study medication. However, only four individuals (two in the ever, only four individuals (two in the placebo and two in the 2 g/day ethyl-EPA placebo and two in the 2 g/day ethyl-EPA groups) failed to complete their assessments groups) failed to complete their assessments at study end-point; for these four the at study end-point; for these four the HRSD, YMRS and CGI scores were extra-HRSD, YMRS and CGI scores were extrapolated using the last-observation-carriedpolated using the last-observation-carriedforward method. Results were analysed on forward method. Results were analysed on an intent-to-treat basis, including partician intent-to-treat basis, including participants who stopped the study medication. pants who stopped the study medication. Table 3 summarises the mean and  Table 3 summarises the mean and standard deviations of the participants' standard deviations of the participants' scores at study entry and end-point. Figures scores at study entry and end-point. Figures  2 and 3 show the changes in HRSD and 2 and 3 show the changes in HRSD and YMRS scores across groups between YMRS scores across groups between baseline and study end-point. There were baseline and study end-point. There were no group differences in episode duration no group differences in episode duration at the time of study entry ( at the time of study entry (F F¼3.9. d.f.
3.9. d.f.¼2, 2, P P¼0.6) or in the baseline scores on 0.6) or in the baseline scores on the HRSD ( the HRSD (F F¼0.8 (d) (d) During the trial, 26 of the 75 randomDuring the trial, 26 of the 75 randomised participants had their medication ised participants had their medication changed or adjusted: 12 in the placebo changed or adjusted: 12 in the placebo group (9 were prescribed new medigroup (9 were prescribed new medication or had the dose of their cation or had the dose of their ongoing medication adjusted because ongoing medication adjusted because of worsening of symptoms and 3 of worsening of symptoms and 3 because of weight gain, oversedation, because of weight gain, oversedation, or high lithium serum levels), 7 in the or high lithium serum levels), 7 in the group receiving 1 g/day of ethyl-EPA group receiving 1 g/day of ethyl-EPA (2 changed lithium dose because of (2 changed lithium dose because of high serum levels and 5 had started high serum levels and 5 had started new medication or increased the dose new medication or increased the dose of their existing drugs because of of their existing drugs because of worsening of symptoms) and 7 in the worsening of symptoms) and 7 in the group receiving 2 g/day of ethyl-EPA group receiving 2 g/day of ethyl-EPA (6 started new medication or had their (6 started new medication or had their dose adjusted because of worsening dose adjusted because of worsening depression, 1 stopped medication depression, 1 stopped medication because of oversedation). because of oversedation).
Of the 75 individuals randomised, 23
Of the 75 individuals randomised, 23 reported emerging side-effects during the reported emerging side-effects during the clinical trial (7 in the placebo arm, 9 in clinical trial (7 in the placebo arm, 9 in the 1 g/day ethyl-EPA and 7 in the 2 g/day the 1 g/day ethyl-EPA and 7 in the 2 g/day ethyl-EPA groups). The most frequently ethyl-EPA groups). The most frequently reported side-effect was loose stools reported side-effect was loose stools (reported by three people in the placebo (reported by three people in the placebo group, three in the 1 g/day ethyl-EPA group, three in the 1 g/day ethyl-EPA group and six in the 2 g/day ethyl-EPA group and six in the 2 g/day ethyl-EPA group), followed by gastrointestinal group), followed by gastrointestinal discomfort (reported by three people in discomfort (reported by three people in the placebo group, one in the 1 g/day the placebo group, one in the 1 g/day ethyl-EPA group and two in the 2 g/day ethyl-EPA group and two in the 2 g/day ethyl-EPA group). There was no difference ethyl-EPA group). There was no difference between the groups in these two types of between the groups in these two types of side-effects ( side-effects (w w 2 2 ¼1.0, d.f.
1.0, d.f.¼2, 2, P P¼0.59). There 0.59). There were also reports of isolated side-effects: were also reports of isolated side-effects: two people in the placebo group reported two people in the placebo group reported constipation, there was one report of nausea constipation, there was one report of nausea and one of flatulence in the 1 g/day ethyland one of flatulence in the 1 g/day ethyl-EPA group and one report of an unpleasant EPA group and one report of an unpleasant taste in the 2 g/day ethyl-EPA group. taste in the 2 g/day ethyl-EPA group.
At study end-point the 71 participants At study end-point the 71 participants (95% of the randomised sample) who com-(95% of the randomised sample) who completed their assessments were asked pleted their assessments were asked whether they thought they had received whether they thought they had received active treatment or not. There were no active treatment or not. There were no group differences regarding participants' group differences regarding participants' ability to guess their group allocation ability to guess their group allocation ( (w w 2 2 ¼1.2, d.f.
1.2, d.f.¼2, 2, P P¼0.5); only 23% of the 0.5); only 23% of the placebo group, 21% of the 1 g/day ethylplacebo group, 21% of the 1 g/day ethyl-EPA and 24% of the 2 g/day ethyl-EPA EPA and 24% of the 2 g/day ethyl-EPA groups guessed their allocation correctly. groups guessed their allocation correctly.
DISCUSSION DISCUSSION
Efficacy of ethyl-EPA in bipolar Efficacy of ethyl-EPA in bipolar depression depression
Treatment of bipolar depression with Treatment of bipolar depression with adjunctive ethyl-EPA resulted in improved adjunctive ethyl-EPA resulted in improved clinical outcomes compared with placebo clinical outcomes compared with placebo in terms of reduction in HRSD and CGI in terms of reduction in HRSD and CGI scores. Improvement was not significantly scores. Improvement was not significantly different in participants treated with different in participants treated with 2 g/ 2 g/ day as opposed to 1 g/day of ethyl-EPA. day as opposed to 1 g/day of ethyl-EPA. Baseline and end-point ratings on the Baseline and end-point ratings on the YMRS were not significantly different YMRS were not significantly different among the three groups. Although there among the three groups. Although there have been reports of hypomania during have been reports of hypomania during treatment with a different preparation of treatment with a different preparation of omega-3 fatty acids (Kinrys, 2000), we omega-3 fatty acids (Kinrys, 2000), we found no evidence that treatment with found no evidence that treatment with ethyl-EPA precipitates polarity changes in ethyl-EPA precipitates polarity changes in people with bipolar disorder. people with bipolar disorder.
Methodological considerations Methodological considerations
There are several methodological issues There are several methodological issues that are worth considering. The placebo that are worth considering. The placebo response rate in clinical trials of bipolar response rate in clinical trials of bipolar depression is high, with a pooled average depression is high, with a pooled average of 29% (Keck of 29% (Keck et al et al, 2000) . To control for , 2000). To control for the influence of psychosocial factors, we the influence of psychosocial factors, we kept the number of assessments and conkept the number of assessments and contacts with the research team at a minimum tacts with the research team at a minimum to minimise the possibility that benefits to minimise the possibility that benefits from treatment could result from increased from treatment could result from increased contact with health professionals. We also contact with health professionals. We also asked participants whether they thought asked participants whether they thought they had received active treatment to examthey had received active treatment to examine whether the significant benefits seen ine whether the significant benefits seen with ethyl-EPA could be attributed to their with ethyl-EPA could be attributed to their guessing correctly their group allocation. guessing correctly their group allocation. We tried to approximate ordinary clinical We tried to approximate ordinary clinical practice by allowing treating physicians to practice by allowing treating physicians to make changes to participants' medication make changes to participants' medication when clinically required. Finally, we anawhen clinically required. Finally, we analysed the data on an intent-to-treat basis lysed the data on an intent-to-treat basis and showed a superior response to ethyland showed a superior response to ethyl-EPA compared with placebo in spite of EPA compared with placebo in spite of the difficulties in finding clear drugthe difficulties in finding clear drugplacebo separation in add-on trials (Keck placebo separation in add-on trials (Keck et al et al, 2000) . This is particularly relevant , 2000). This is particularly relevant here since about half of those randomised here since about half of those randomised to the placebo group had their medication to the placebo group had their medication adjusted when their symptoms persisted or adjusted when their symptoms persisted or worsened. worsened.
Possible mechanism of action Possible mechanism of action of ethyl-EPA of ethyl-EPA
The precise mechanism of action of ethylThe precise mechanism of action of ethyl-EPA in improving bipolar depression is EPA in improving bipolar depression is not clear. Antidepressants exert their action not clear. Antidepressants exert their action at the level of neurotransmitters (catecholaat the level of neurotransmitters (catecholamines and serotonin) and neurotransmitter mines and serotonin) and neurotransmitter .3) 3.6 (2.9) 3.6 (2.9) 2.9 (2.6) 2.9 (2.6)
Participants with a lifetime history of psychosis within episodes, Participants with a lifetime history of psychosis within episodes, n n (%) (%) 21 (81) 21 (81) 15 (63) 15 (63) 17 (68) 17 (68) EPA, eicosapentaenoic acid. EPA, eicosapentaenoic acid. (Stoll & Severus, 1996) . Omega-3 tems (Stoll & Severus, 1996) . Omega-3 fatty acids such as ethyl-EPA may be simifatty acids such as ethyl-EPA may be similar to mood stabilisers in this respect. It is lar to mood stabilisers in this respect. It is possible that the incorporation of EPA into possible that the incorporation of EPA into cell membranes inhibits the action of phoscell membranes inhibits the action of phospholipase A pholipase A 2 2 , an enzyme that is important , an enzyme that is important for the production of second messenger for the production of second messenger molecules such as arachidonic acid (Finnen molecules such as arachidonic acid ) of the antidepressant effect of omega-3 fatty acids, particularly effect of omega-3 fatty acids, particularly of ethyl-EPA. They also strongly suggest of ethyl-EPA. They also strongly suggest that treatment with ethyl-EPA is not assothat treatment with ethyl-EPA is not associated with increased risk of inducing ciated with increased risk of inducing manic symptoms. At the doses prescribed manic symptoms. At the doses prescribed here the side-effects were minimal and inhere the side-effects were minimal and indistinguishable from those in the placebo distinguishable from those in the placebo group. Although the role of ethyl-EPA in group. Although the role of ethyl-EPA in the treatment of bipolar disorder requires the treatment of bipolar disorder requires further evaluation, our results offer further evaluation, our results offer optimism that ethyl-EPA represents a new optimism that ethyl-EPA represents a new generation of naturally occurring and safe generation of naturally occurring and safe psychotropic compounds. psychotropic compounds.
